Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157296 | 0.83 | NOS3 (0.42) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL20149755 | 0.83 | NOS3 (0.42) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL1039344 | 0.81 | NOS3 (0.43) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL3636398 | 0.81 | NOS3 (0.48) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL4998230 | 0.81 | KDM4E (0.45) | NOS3NOS1NOS2KMT2APLAU | |
| Hydrochloric Acid SCHEMBL27558535 | 0.79 | KDM4E (0.44) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL31527719 | 0.79 | KMT2A (0.49) | NOS3NOS1NOS2KMT2APLAU | |
| SCHEMBL10833748 | 0.78 | MAPK1 (0.41) | KMT2APAX8PTGS2PTGS1KDM4E | |
| SCHEMBL2645585 | 0.78 | KMT2A (0.40) | KMT2APAX8PTGS2PTGS1KDM4E | |
| SCHEMBL24351473 | 0.78 | NOS3 (0.41) | NOS3NOS1NOS2KMT2APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191953-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2023-10-05 | — | — | WO | disclosed |
| US-9394302-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2794600-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | Novartis AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| CN-101248049-B | Imidazole based lxr modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| WO-2013093849-A1 | DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| CN-101248049-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NOS3 1334/4885NOS1 2085/4885NOS2 1956/4885 |
| US-20140031393-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NOS3 1334/4885NOS1 2085/4885NOS2 1956/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | NOS3 3395/4885NOS1 3878/4885NOS2 3241/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | NOS3 1334/4885NOS1 2085/4885NOS2 1956/4885 |
| US-20150191468-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | NOS3 3318/4885NOS1 2467/4885NOS2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.